PMC:7408073 / 82366-82549 JSONTXT

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T158","span":{"begin":38,"end":41},"obj":"Body_part"}],"attributes":[{"id":"A158","pred":"uberon_id","subj":"T158","obj":"http://purl.obolibrary.org/obo/UBERON_0018229"}],"text":"rmine a Rationale Use of the Specific RAS Inhibitors\nThere is currently no specific pharmacotherapy to combat SARS-CoV-2 infection and its pathological effects. Actually, the use of p"}

{"project":"LitCovid-PubTator","denotations":[{"id":"2897","span":{"begin":110,"end":130},"obj":"Disease"}],"attributes":[{"id":"A2897","pred":"tao:has_database_id","subj":"2897","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"rmine a Rationale Use of the Specific RAS Inhibitors\nThere is currently no specific pharmacotherapy to combat SARS-CoV-2 infection and its pathological effects. Actually, the use of p"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T459","span":{"begin":110,"end":118},"obj":"Disease"},{"id":"T460","span":{"begin":110,"end":114},"obj":"Disease"},{"id":"T461","span":{"begin":121,"end":130},"obj":"Disease"}],"attributes":[{"id":"A459","pred":"mondo_id","subj":"T459","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A460","pred":"mondo_id","subj":"T460","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A461","pred":"mondo_id","subj":"T461","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"rmine a Rationale Use of the Specific RAS Inhibitors\nThere is currently no specific pharmacotherapy to combat SARS-CoV-2 infection and its pathological effects. Actually, the use of p"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T993","span":{"begin":6,"end":7},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"rmine a Rationale Use of the Specific RAS Inhibitors\nThere is currently no specific pharmacotherapy to combat SARS-CoV-2 infection and its pathological effects. Actually, the use of p"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T94142","span":{"begin":38,"end":41},"obj":"Chemical"}],"attributes":[{"id":"A26261","pred":"chebi_id","subj":"T94142","obj":"http://purl.obolibrary.org/obo/CHEBI_63620"}],"text":"rmine a Rationale Use of the Specific RAS Inhibitors\nThere is currently no specific pharmacotherapy to combat SARS-CoV-2 infection and its pathological effects. Actually, the use of p"}

{"project":"LitCovid-sentences","denotations":[{"id":"T405","span":{"begin":53,"end":160},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"rmine a Rationale Use of the Specific RAS Inhibitors\nThere is currently no specific pharmacotherapy to combat SARS-CoV-2 infection and its pathological effects. Actually, the use of p"}